Oncology Innovation Outpaces Managed Care’s Ability to Keep Up

Why It Matters

These gaps drive higher costs, uneven patient outcomes, and force payers to redesign coverage and care‑coordination models to keep pace with innovation.

Key Takeaways

• Only 35.6% of eligible NSCLC patients receive targeted therapy
• DPYD testing $175 can avoid $180k toxicity treatment costs
• CAR‑T therapies now approved for seven cancers, moving to community sites
• Clinical pathway adherence fell from 74% to 60% between 2018‑2021

Pulse Analysis

Precision oncology promises to match the right drug to the right patient, yet execution remains fragmented. Biomarker testing now spans diagnosis to surveillance, but state‑level coverage policies are inconsistent, leaving many patients without timely tests. The DPYD example illustrates how a low‑cost genetic screen can avert catastrophic toxicity and billions in downstream spending, underscoring the need for uniform payer mandates.

CAR‑T therapy exemplifies how once‑niche, high‑cost treatments are becoming mainstream. With seven FDA‑approved products covering multiple hematologic and solid‑tumor indications, regulatory relief—such as the 2025 REMS removal—has lowered administrative barriers. Community‑based accreditation pathways are expanding access, but rural patients still face travel hurdles, prompting payers to consider decentralized infusion models and bundled payment structures.

Traditional utilization tools like prior authorizations and static clinical pathways are losing relevance amid rapid drug approvals and complex biomarker requirements. Studies show pathway adherence dropping from 74% to 60% over three years, correlating with higher emergency visits and hospitalizations. Virtual navigation platforms are emerging as a cost‑effective solution, guiding patients through testing, treatment selection, and supportive care, thereby reducing acute‑care utilization and aligning spend with value‑based goals. Payers that integrate these digital tools will be better positioned to manage the $180 billion oncology market projected for 2028.